Oppenheimer Has Lowered Expectations for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its target price cut by equities researchers at Oppenheimer from $200.00 to $125.00 in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would indicate a potential upside of 52.59% from the stock’s current price.

Several other equities analysts have also commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a report on Monday, October 7th. Needham & Company LLC decreased their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday. Canaccord Genuity Group upped their target price on TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Trading Down 7.4 %

Shares of TransMedics Group stock opened at $81.92 on Tuesday. TransMedics Group has a 52-week low of $36.42 and a 52-week high of $177.37. The stock has a market cap of $2.73 billion, a PE ratio of 87.15 and a beta of 1.99. The firm has a 50-day moving average of $144.20 and a 200-day moving average of $139.76. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the previous year, the company earned ($0.12) EPS. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, sell-side analysts forecast that TransMedics Group will post 1.22 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in TMDX. International Assets Investment Management LLC bought a new stake in TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas acquired a new position in shares of TransMedics Group in the 3rd quarter worth approximately $55,000. J.Safra Asset Management Corp boosted its stake in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC increased its position in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Fidelis Capital Partners LLC bought a new position in TransMedics Group during the first quarter worth $35,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.